Morepen Laboratories Limited
Momentum (95/100) does the heavy lifting; financial trend (20/100) is the drag.
Buy zoneOur blended model reads Morepen Laboratories Limited as a Buy at 61/100. At ₹57.04 it trades below our blended DCF and relative-multiples fair value of ₹71.92, about 26% upside to that estimate — we read it as undervalued by 26%. On 31.1x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 9% below its 52-week high of ₹62.68 and 69% above the low of ₹33.68. Financial health scores 64/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. It clears 7 of 13 investability checks, with durability 41, valuation 76 and momentum 95 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹57.53.
1-year price
EOD · 2026-07-3152-week range
-9.00% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy61Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 7.9%
- Pass: Low debt (D/E < 0.5): 0.17x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 4%
- Fail: Earnings growing: -19%
- Fail: Net margin ≥ 10%: 5.3%
- Pass: Current ratio > 1.5: 2.37
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 3.57
- Fail: Piotroski ≥ 7: 6/9
Shareholding
- Promoter43.7%
- Institutions1.4%
- Public & other54.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 3.57.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~26% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (7.9%).
Threats
- Earnings contracting year on year.
About Morepen Laboratories Limited
Morepen Laboratories manufactures and sells active pharmaceutical ingredients and branded and generic drug formulations across India, the United States, and international markets. The company produces APIs for antihistamine, antiasthmatic, antilipemic, antihypertensive, antidiabetic, anticoagulant, antiulcerative, and antidepressant medications, along with home health diagnostic products including air purifiers, sphygmomanometers, and blood glucose monitors.
Morepen Laboratories Limited — frequently asked questions
Is Morepen Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Morepen Laboratories Limited (MOREPENLAB) a Buy, based on a blended score of 61/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Morepen Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Morepen Laboratories Limited's fair value at about ₹71.92, versus a current price of ₹57.04 — roughly 26% upside. On that basis the stock looks undervalued by 26%.
Is Morepen Laboratories Limited financially healthy?
Morepen Laboratories Limited scores 64/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Morepen Laboratories Limited's share price performed?
Morepen Laboratories Limited is up 36% over three months, and last traded at ₹57.04. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.